Linatab E Tablet 25 mg + 5 mg is a combination oral antidiabetic medication designed to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It combines Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This dual mechanism targets blood sugar control through complementary pathways, offering enhanced efficacy with once-daily dosing.

Linatab E is indicated for patients whose blood glucose is not adequately controlled with diet and exercise alone or as an adjunct to other antidiabetic therapies. The combination helps reduce fasting and postprandial glucose levels while supporting weight management and cardiovascular health.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Empagliflozin: SGLT2 inhibitor

• Linagliptin: DPP-4 inhibitor

• Overall Class: Combination antidiabetic therapy

Pharmacology

Empagliflozin:
Empagliflozin works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose from urine back into the bloodstream. By blocking SGLT2, more glucose is excreted in urine, lowering blood sugar levels independently of insulin. Empagliflozin also offers cardiovascular and renal benefits in patients with T2DM.

Linagliptin:
Linagliptin selectively inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 and GIP. By prolonging the activity of incretins, Linagliptin enhances glucose-dependent insulin secretion and reduces glucagon release, helping to regulate postprandial blood sugar without causing significant hypoglycemia.

Combination Effect:
By combining Empagliflozin and Linagliptin, Linatab E offers synergistic effects, improving both fasting and postprandial glucose levels while reducing the risk of hypoglycemia compared to some other antidiabetic agents.

Indications

Linatab E Tablet 25 mg + 5 mg is indicated in adults with type 2 diabetes mellitus for:

• Improving glycemic control when diet and exercise alone are insufficient

• Adjunct therapy in combination with other antidiabetic medications

• Reducing the risk of cardiovascular events in patients with T2DM and established cardiovascular disease (due to Empagliflozin component)

Dosage and Administration

• Recommended dose: 1 tablet orally once daily, taken in the morning with or without food

• Adjustment: No dose adjustment is typically required for mild renal impairment. Caution is advised in moderate to severe renal impairment.

• Patients should maintain adequate hydration while taking Empagliflozin to prevent dehydration or hypotension.

Contraindications

• Type 1 diabetes mellitus

• History of hypersensitivity to Empagliflozin, Linagliptin, or any excipients

• Severe renal impairment, end-stage renal disease, or patients on dialysis

• Active bladder cancer (for Empagliflozin, rare reports)

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Linatab E is generally well tolerated. Common side effects include:

• Urinary tract infections

• Genital mycotic infections

• Nasopharyngitis

• Hypoglycemia (when combined with insulin or sulfonylureas)
  Rare but serious side effects:

• Ketoacidosis

• Acute kidney injury

• Pancreatitis

Precautions and Warnings

• Monitor renal function before and during therapy

• Discontinue during acute illness, dehydration, or surgery to reduce risk of ketoacidosis

• Educate patients on signs of genital infections and proper hygiene

Pregnancy and Lactation

• Not recommended during pregnancy or breastfeeding. Use only if clearly needed and after assessing risks vs benefits.

Storage Conditions

Store at room temperature below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children.